Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

161. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General

Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Pandemic influenza preparedness: sharing of influenza (...) viruses and access to vaccines and other benefits: report by the Director-General View/ Open View Statistics Altmetrics Share Citation World Health Assembly, 69 . (‎2016)‎. Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits: report by the Director-General. World Health Organization. Gov't Doc # A69/22 Add.2 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Assembly, 63 (‎ A63/48

2016 WHO

162. WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation

WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation View/ Open View Statistics Altmetrics (...) Share Citation World Health Organization . (‎2016)‎. WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation. World Health Organization. Description 39 p. Gov't Doc # WHO/HIS/TTi/GAP/16.1 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Organization (‎ 1998 )‎  World Health Assembly, 63 (‎ A63/48 , 2010 )‎  World Health Assembly, 64 (‎ A64/8A64/8 Corr.1 , 2011 )‎ View Item

2016 WHO

163. Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016

Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016 Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Barriers of influenza vaccination intention and behavior: a systematic review (...) of influenza vaccine hesitancy 2005 – 2016 View/ Open View Statistics Altmetrics Share Citation World Health Organization . (‎2016)‎. Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016. World Health Organization. Description 72 p. Gov't Doc # WHO/HIS/TTi/GAP/16.2 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Assembly, 71 (‎ A71/24 , 2018 )‎  World Health Organization

2016 WHO

164. Cohort study: Influenza vaccination and egg allergy: another step forward

Cohort study: Influenza vaccination and egg allergy: another step forward Influenza vaccination and egg allergy: another step forward | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Influenza vaccination and egg allergy: another step forward Article Text Aetiology/Harm Cohort study Influenza vaccination and egg allergy: another step forward Anne Des Roches , Louis Paradis Statistics from Altmetric.com Commentary on: Turner PJ

2016 Evidence-Based Medicine (Requires free registration)

165. Immunizations - seasonal influenza

Immunizations - seasonal influenza Immunizations - seasonal influenza - NICE CKS Clinical Knowledge Summaries Share Immunizations - seasonal influenza: Summary Influenza is an acute viral infection of the respiratory tract. Influenza types A and B are responsible for most cases of clinical illness in the UK. In healthy people, seasonal influenza is usually a self-limiting disease with recovery in 2–7 days. However, in older people and those in clinical risk groups, it can result in serious (...) complications such as pneumonia, meningitis, encephalitis, or death. Seasonal influenza immunization is recommended for people at increased risk of complications, including: All people 65 years of age and older. All people aged between 6 months to under 65 years who are in a clinical risk group, such as people with chronic respiratory, heart, kidney, liver, or neurological disease; people with diabetes mellitus; people who are immunosuppressed or immunocompromised, pregnant women, and people with morbid

2016 NICE Clinical Knowledge Summaries

166. Tool for Influenza Pandemic Risk Assessment (TIPRA)

Tool for Influenza Pandemic Risk Assessment (TIPRA) Tool for Influenza Pandemic Risk Assessment (‎TIPRA)‎ JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Tool for Influenza Pandemic Risk Assessment (‎TIPRA)‎ View/ Open View Statistics Altmetrics Share Citation World Health Organization . (‎2016)‎. Tool for Influenza Pandemic Risk Assessment (‎TIPRA)‎. World Health Organization

2016 WHO

167. Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza (Feb 2016)

Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza (Feb 2016) DRAFT SCIENTIFIC ADVICE FOR CONSULTATION ECDC PRELIMINARY SCIENTIFIC ADVICE Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza Review of recent systematic reviews and meta-analyses ii This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Pasi Penttinen and Kari Johansen. Contributing authors Emmanuel Robesyn, Eeva Broberg (...) under copyright and cannot be used for purposes other than this publication without the express permission of the copyright holder. SCIENTIFIC ADVICE Expert Opinion on Neuraminidase inhibitors for prevention and treatment of influenza iii Contents Abbreviations iv Glossary v Executive summary 1 Background 3 Request for ECDC Expert Opinion 5 Methods 6 Results and discussion 8 General characteristics of the systematic reviews and meta-analyses reviewed by ECDC expert group 8 Treatment of outpatients

2016 European Centre for Disease Prevention and Control - Expert Opinion

168. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. (PubMed)

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. How safe is live attenuated influenza vaccine (LAIV), which contains egg protein, in young people with egg allergy?In this open label, phase IV intervention study, 779 young people (2-18 years) with egg allergy were recruited from 30 UK allergy centres and immunised with LAIV. The cohort included 270 (34.7%) young people with previous anaphylaxis to egg, of whom 157 (20.1%) had

Full Text available with Trip Pro

2015 BMJ

169. Nosocomial transmission of avian influenza A (H7N9) virus in China: epidemiological investigation. (PubMed)

Nosocomial transmission of avian influenza A (H7N9) virus in China: epidemiological investigation. Can avian influenza A (H7N9) virus be transmitted between unrelated individuals in a hospital setting?An epidemiological investigation looked at two patients who shared a hospital ward in February 2015, in Quzhou, Zhejiang Province, China. Samples from the patients, close contacts, and local environments were examined by real time reverse transcriptase (rRT) polymerase chain reaction (PCR (...) ) and viral culture. Haemagglutination inhibition and microneutralisation assays were used to detect specific antibodies to the viruses. Primary outcomes were clinical data, infection source tracing, phylogenetic tree analysis, and serological results.A 49 year old man (index patient) became ill seven days after visiting a live poultry market. A 57 year old man (second patient), with a history of chronic obstructive pulmonary disease, developed influenza-like symptoms after sharing the same hospital ward

Full Text available with Trip Pro

2015 BMJ

170. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. (PubMed)

Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. What is the mortality in offspring of mothers who had influenza A(H1N1)pdm09 vaccination during pregnancy?This was a prospective population based cohort study in seven healthcare regions in Sweden based on vaccinations taking place between 2 October 2009 and 26 November 2010. H1N1 vaccination data were linked with pregnancy and birth characteristics and offspring mortality data (...) in 275,500 births (of which 1203 were stillbirths) from 137,886 mothers. Of these offspring, 41,183 had been exposed to vaccination with Pandemrix, a monovalent AS03 adjuvanted H1N1 influenza vaccine, during fetal life. A primary comparison group consisted of pregnancies of women who were not vaccinated during the same calendar period. In a second comparison, non-exposed siblings of infants prenatally exposed to vaccination were used as controls. Cox regression was used to estimate hazard ratios

Full Text available with Trip Pro

2015 BMJ

171. Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2015-2016

Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2015-2016 NACI Statement: Seasonal Influenza Vaccine: 2015–2016 - Canada.ca Language selection Search Search Canada.ca Search Menu Main Menu You are here: NACI Statement: Seasonal Influenza Vaccine: 2015–2016 Published by: Issue: Date published: October 1, 2015 ISSN: 1481-8531 Submit a manuscript About CCDR Browse Volume 41-10, October 1, 2015: Vaccines Advisory Committee Statement (...) Summary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2015–2016 Gemmill I 1,2 , on behalf of the National Advisory Committee on Immunization (NACI)* Affiliations 1 Chair, NACI 2 Kingston, Frontenac and Lennox & Addington Public Health, Kingston, ON Correspondence DOI https://doi.org/10.14745/ccdr.v41i10a02 Abstract Background: The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada with ongoing

2015 CPG Infobase

172. Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. (PubMed)

Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. Few studies have evaluated the relationship between influenza vaccination and pneumonia, a serious complication of influenza infection.To assess the association between influenza vaccination status and hospitalization for community-acquired laboratory-confirmed influenza pneumonia.The Etiology of Pneumonia in the Community (EPIC) study (...) was a prospective observational multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010 through June 2012 at 4 US sites. In this case-control study, we used EPIC data from patients 6 months or older with laboratory-confirmed influenza infection and verified vaccination status during the influenza seasons and excluded patients with recent hospitalization, from chronic care residential facilities, and with severe immunosuppression. Logistic regression was used

Full Text available with Trip Pro

2015 JAMA

173. Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study

Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found

Full Text available with Trip Pro

2015 NIHR HTA programme

174. Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza

Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza NCCEH Fact Sheet: Non-pharmaceutical measures to prevent the transmission of in? uenza This fact sheet is for public health professionals. It provides a brief overview on speci? c non-pharmaceutical measures to be used in community settings. Such measures can prevent the spread of in? uenza by interrupting the transfer of viruses from objects or people through the use of personal protective equipment or changes

2015 National Collaborating Centre for Environmental Health

175. Human Infection with a Novel Avian Influenza A(H5N6) Virus. (PubMed)

Human Infection with a Novel Avian Influenza A(H5N6) Virus. 26222578 2015 08 14 2016 11 25 1533-4406 373 5 2015 Jul 30 The New England journal of medicine N. Engl. J. Med. Human Infection with a Novel Avian Influenza A(H5N6) Virus. 487-9 10.1056/NEJMc1502983 Yang Zi-Feng ZF State Key Laboratory of Respiratory Disease, Guangzhou, China. Mok Chris K P CK Peiris Joseph S M JS Zhong Nan-Shan NS eng Case Reports Letter Research Support, Non-U.S. Gov't United States N Engl J Med 0255562 0028-4793 AIM (...) IM Animals China Humans Influenza A virus classification isolation & purification Influenza in Birds Influenza, Human diagnosis therapy virology Lung diagnostic imaging pathology Male Middle Aged Poultry Radiography 2015 7 30 6 0 2015 7 30 6 0 2015 8 15 6 0 ppublish 26222578 10.1056/NEJMc1502983

Full Text available with Trip Pro

2015 NEJM

176. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. (PubMed)

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Human infections with the avian influenza A(H7N9) virus were first reported in China in 2013 and continue to occur. Hemagglutinin H7 administered alone is a poor immunogen necessitating evaluation of adjuvanted H7N9 vaccines.To evaluate the immunogenicity and safety of an inactivated H7N9 vaccine with and without AS03 adjuvant, as well as mixed (...)  = 96) (103.4 [95% CI, 78.7-135.9]; P < .001) but higher GMTs than 2 doses of MF59-adjuvanted formulation (n = 94) (29.0 [95% CI, 22.4-37.6]; P < .001).The AS03 and MF59 adjuvants augmented the immune responses to 2 doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest titers. This study of 2 adjuvants used in influenza vaccine formulations with adjuvant mixed on site provides immunogenicity information that may be informative to influenza pandemic

Full Text available with Trip Pro

2015 JAMA

177. Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE)

Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Journals Library An error has

Full Text available with Trip Pro

2015 NIHR HTA programme

178. Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes. (PubMed)

Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes. Infections during pregnancy confers increased risk of maternal and perinatal morbidity and mortality. However, the case for advocating Haemophilus influenzae type B (Hib) and viral Influenza vaccinations in pregnancy is still debatable.To assess the impact of Hib and viral Influenza vaccinations during pregnancy on maternal, neonatal and infant (...) health outcomes compared to placebo/control.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (29 January 2015) and reference lists of retrieved studies.All randomised controlled clinical trials (including cluster-randomised trials) and quasi-randomised trials evaluating Hib or viral influenza vaccination during pregnancy compared with no vaccination or placebo.Two review authors independently assessed trials for inclusion, risk of bias and extracted data. Data were checked

Full Text available with Trip Pro

2015 Cochrane

179. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. (PubMed)

Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Despite widespread use, questions remain about the efficacy of oseltamivir in the treatment of influenza. We aimed to do an individual patient data meta-analysis for all clinical trials comparing oseltamivir with placebo for treatment of seasonal influenza in adults regarding symptom alleviation, complications, and safety.We included all published and unpublished Roche-sponsored randomised placebo (...) -controlled, double-blind trials of 75 mg twice a day oseltamivir in adults. Trials of oseltamivir for treatment of naturally occurring influenza-like illness in adults reporting at least one of the study outcomes were eligible. We also searched Medline, PubMed, Embase, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov trials register for other relevant trials published before Jan 1, 2014 (search last updated on Nov 27, 2014). We analysed intention-to-treat infected, intention

2015 Lancet

180. Interventions effective in increasing influenza vaccination rates

Interventions effective in increasing influenza vaccination rates Interventions effective in increasing influenza vaccination rates | Cochrane Primary Care Trusted evidence. Informed decisions. Better health. Enter terms Interventions effective in increasing influenza vaccination rates Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2019 The Cochrane Collaboration | | We use cookies to improve your experience on our site.

2015 Cochrane PEARLS